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Depression after stroke is a common occurrence, raising questions as to whether 
depression could be a long-term biological and immunological sequela of stroke. Early 
explanations for post-stroke depression (PSD) focused on the neuropsychological/
psychosocial effects of stroke on mobility and quality of life. However, recent investiga-
tions have revealed imbalances of inflammatory cytokine levels in association with PSD, 
though to date, there is only one published proteomic pathway analysis testing this 
hypothesis. Thus, we examined the serum proteome of stroke patients (n = 44, mean 
age = 63.62 years) and correlated these with the Montgomery–Åsberg Depression Rating 
Scale (MADRS) scores at 3 months post-stroke. Overall, the patients presented with mild 
depression symptoms on the MADRS, M = 6.40 (SD = 7.42). A discovery approach uti-
lizing label-free relative quantification was employed utilizing an LC-ESI–MS/MS coupled 
to a LTQ-Orbitrap Elite (Thermo-Scientific). Identified peptides were analyzed using the 
Abbreviations: ApoA4, ApoC2, APOE, apolipoproteins A4, C2, E; BBB, blood–brain barrier; C6, C3, C3a, C5a, comple-
ment component 6, 3, 3 a, 5a; EDTA, ethylenediaminetetraacetic acid; ESI, electrospray ionization; FDR, false discovery rate; 
GO, Gene Ontology; GSEA, gene set enrichment analysis; GSN, gelsolin; ITRAQ, isobaric tagging for relative and absolute 
quantification; KEGG, Kyoto Encyclopedia of Genes and Genomes; LC, liquid chromatography; LFQ, label-free quantification; 
MADRS, Montgomery–Åsberg Depression Rating Scale; MAC, membrane attack complex; MS, MS/MS, mass spectrometry, 
tandem mass spectrometry; MBL2, mannan-binding lectin 2; MoCA, Montreal Cognitive Assessment; mRS, modified Rankin 
Scale; NES, normalized enrichment score; NIHSS, National Institute of Health Stroke Scale; PHQ-9, PHQ-2, Patient Health 
Questionnaire 9, 2; PrePARE, Prediction and Prevention to Achieve optimal Recovery Endpoints; PSD, post-stroke depression; 
RNA, ribonucleic acid; S100A12, S100 calcium-binding protein A12; SIGMA, structured interview guide for the Montgomery–
Åsberg Depression Rating Scale; SLE, systemic lupus erythematous; START, STroke imAging, pRevention and Treatment 
longitudinal stroke cohort study; TF, transferring; TIA, transient ischemic attack; TLR4, toll-like receptor 4; TOAST, trial of 
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gene set enrichment approach on several different genomic databases that all indicated 
significant downregulation of the complement and coagulation systems with increasing 
MADRS scores. Complement and coagulation systems are traditionally thought to play 
a key role in the innate immune system and are established precursors to the adaptive 
immune system through pro-inflammatory cytokine signaling. Both systems are known 
to be globally affected after ischemic or hemorrhagic stroke. Thus, our results suggest 
that lowered complement expression in the periphery in conjunction with depressive 
symptoms post-stroke may be a biomarker for incomplete recovery of brain metabolic 
needs, homeostasis, and inflammation following ischemic stroke damage. Further pro-
teomic investigations are now required to construct the temporal profile, leading from 
acute lesion damage to manifestation of depressive symptoms. Overall, the findings 
provide support for the involvement of inflammatory and immune mechanisms in PSD 
symptoms and further demonstrate the value and feasibility of the proteomic approach 
in stroke research.
Keywords: ischemic stroke, proteomics, post-stroke depression, complement and coagulation, immunity and 
inflammation, stroke neurological recovery, blood biomarkers
inTrODUcTiOn
Over 15 million people worldwide experience a stroke each year; 
5 million of those events are fatal, and another 5 million people 
are left with a permanent disability (1). Previous epidemiological 
reviews have concluded that ~30% of stroke survivors are likely 
to experience post-stroke depression (PSD) (2, 3). Prevalence of 
depression is stroke survivors is reported to peak at 3  months 
post-stroke based on testing using the Diagnostic and Statistical 
Manual V [DSM-V (4)] (5). Studies have also characterized 
depression symptoms on the same criteria as early as 15  days 
and as late as 12  months post-stroke (5). Stroke patients with 
PSD show poorer functional and recovery outcomes compared 
to patients not suffering depression (6, 7). PSD is also found to 
contribute to poorer quality of life and increased mortality rates 
(1, 6), thus highlighting the need for patient care that extends 
beyond that of physical and cognitive rehabilitation. Investigation 
of biomarkers linked with underlying mechanisms has potential 
to guide the targeting of therapy, both prevention and treatment.
Currently, there is no consensus regarding the etiology of PSD 
with much debate as to the extent to which PSD stems from a 
purely biological origin and/or more likely incorporates elements 
of psychosocial response (7, 8). Following the biological argument 
for PSD progression, it was first proposed that the location of the 
stroke lesion could predict PSD presentation (9). This has been 
long debated without resolution (10). More recently, basal ganglia 
or frontal lobe lesions (7), white matter hyperintensities (11), and 
interruption of connecting pathways (12) have been linked to 
PSD. Furthermore, a recent review suggests that right hemisphere 
stroke predicts PSD incidence in the sub-acute, 1–6 months post-
stroke period (13). Other explanations for correlations between 
PSD symptoms and stroke lesions have suggested that the overall 
balance of monoamines, such as serotonin, dopamine, and 
norepinephrine, are disrupted following cerebrovascular damage 
(14). These same amines have previously been associated with 
depression, consistent with a link between stroke and depressive 
symptoms (15).
Other reviews and meta-analyses have failed to find clear 
evidence for lesion location as a risk factor for PSD (3, 5). For 
instance, similar incidence rates of comorbid depression can be 
seen in other cerebrovascular diseases such as vascular dementia in 
the elderly where brain lesions are common (16, 17). Surprisingly, 
prevalence rates of depression are also similar in patients who 
have been subject to transient ischemic attacks (TIAs) (18–20) 
or carotid artery stenosis patients (21), where there is little to no 
presentation of lesions visible on computerized axial tomogra-
phy or magnetic resonance imaging (MRI). In TIA especially, 
prevalence of PSD is comparable to stroke even at 12  months 
post-stroke (19). Thus, while currently detectable brain lesions 
may contribute to the etiology of PSD, they are unlikely to be 
the primary cause with evidence suggesting other pathogenesis 
involving immune disruption and circulating cytokines long after 
the stroke (22).
It is possible that PSD could be viewed as depression resulting 
first from damage caused by the initial ischemia and reperfu-
sion injury (23) and exacerbated by psychosocial issues such 
as anxiety, loss of confidence, and apathy associated with even 
mild loss of mobility or functioning (24). In line with this view, 
the cytokine hypothesis proposes a role for pro-inflammatory 
cytokines such as tumor necrosis factor α, interleukin-1 (IL-1), 
IL-6, IL-8, and anti-inflammatory IL-10. This is consistent with 
evidence that pro-inflammatory cytokines have been found to be 
increased in both depressive mood (25, 26) and cerebrovascular 
events (8, 16, 27, 28). Pro-inflammatory cytokine levels are 
elevated during and long after the therapeutic window of typical 
tissue plasminogen activator treatment (tPA; <4.5  h) (16, 29, 
30). Recent immunoassay research has established that cytokine 
levels often remained significantly elevated at 1 year post-stroke, 
leading the authors to suggest that the homeostatic balance of 
pro- and  anti-inflammatory cytokines may be disrupted in the 
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long term (31). Elevated pro-inflammatory cytokine expression 
is also likely to influence glucocorticoid resistance and sensitivity, 
which is reported to lead to overactivation of the hypothalamus–
pituitary–adrenal (HPA) axis, thereby inducing depressive mood 
(32–34). Furthermore, persistently high concentrations of pro-
inflammatory cytokine levels may provide functional markers 
for long-term impaired immunological responses as the body 
attempts to resolve the lesion-induced neurodegeneration.
Given the multifaceted nature of PSD, it is difficult to ascertain 
the underlying molecular basis of stroke damage associated with 
depressive symptoms at the 3-month peak prevalence period 
in human patients. In recent years, proteomics has provided a 
powerful platform for pathology research. Downstream from 
transcriptomic processes, the proteome describes the totality of 
proteins that can be produced by the organism’s genome. The 
complexity of the proteome accounts for the biological function-
ing of an organism and as such includes not only the primary 
function of the protein itself but also how it fits into the biologi-
cal environment that is further determined by protein–protein 
interactions, posttranslational modifications (35), and protein 
degradation. With the addition of alternative splicing to these 
processes, the 25,000 genes in the human genome can theoreti-
cally encode up to 1,000,000 different proteins (36). To this end, 
proteomics approaches coupled with bioinformatics have proven 
useful in identifying potential therapeutic biomarkers in patholo-
gies including cancer (37) and cardiovascular disease (36). In the 
case of proteomic disease research, biomarkers refer to a subset 
of proteins that are upregulated, downregulated, activated, or 
deactivated and are detectable using a particular methodology in 
a disease phenotype.
The proteomic composition of a biological organism can 
reflect not only rapid changes in response to external challenges 
(38, 39) but also can be studied to understand disease progression 
and biological changes in the long term (40, 41). In stroke, the 
damage caused by the event would be expected to show both 
acute and later chronic consequences. A discovery proteomics 
approach utilizing a mass spectrometer with high dynamic range 
in order to assay as much of the human proteome as possible 
is therefore warranted in the context of proteome complexity 
and the multifactorial nature of PSD etiology. Previous studies 
adopting this approach have been successful in providing new 
insights and support for the interpretation of molecular bio-
logical mechanisms following a stroke (42). The majority of these 
studies focused on revealing biomarkers that might be useful 
aids to rapid diagnosis, for example, in the case of differentiation 
between hemorrhagic stroke versus ischemic stroke (43) and 
ischemic stroke versus healthy controls (44). Research has also 
been successful in characterizing the treatment effects of tPA (45) 
and electroacupuncture (46) on the human proteome, demon-
strating that proteomics approaches can objectively characterize 
the molecular changes associated with certain treatments.
A review of the literature up to December 2015 revealed 
only a single published study examining the proteomic profile 
of PSD. Isobaric tagging for relative and absolute quantification 
(iTRAQ) was employed by Zhan and colleagues (47) to compare 
the ethylenediaminetetraacetic acid (EDTA) anticoagulated 
blood of patients with stroke and PSD, stroke without PSD, and 
healthy controls. The iTRAQ approach involves isobaric tagging 
of tryptic digested samples based on phenotypes of interest for 
comparison through commercially available iTRAQ reagents 
and thus facilitates proteome to proteome comparisons of dis-
ease versus control groups (48). This is conducted by introducing 
a pooled mixture of all the samples to the mass spectrometer, 
whereby relative quantitation can be assessed by comparing 
differences in the peak intensity between labeled peptides (49), 
an approach well suited for investigations of disease phenotypes. 
The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) bioinformatics tool for gene enrichment 
revealed that of the peptides that statistically differentiated 
stroke patients with and without PSD, only the complement and 
coagulation cascade pathway accounted for the clustering of 
identified proteins. Given that this research was conducted on 
patients at 1 month post-stroke, it was suggested that these find-
ings indicate a homeostatic imbalance of pro-inflammatory and 
anti-inflammatory processes in PSD (47). These findings are in 
line with the principles of the cytokine hypothesis of PSD, albeit 
complement pathways are more reliably identifiable in blood as 
biomarkers of immune disruption (50, 51). Zhan and colleagues 
(47) also further examined the top protein candidates by protein 
immunoblotting of apolipoproteins A IV (ApoA-4) and C-II 
(ApoC-2), C-reactive protein (CRP), gelsolin, haptoglobin, 
and leucine-rich glycoprotein (LRG). All of these proteins were 
significantly altered in PSD patients compared to stroke without 
depression. As there are limited data on the biological processes 
directly involved in PSD, Zhan et  al.’s (47) study represents a 
successful first step in applying proteomics approaches to PSD, 
a disorder that has been previously difficult to characterize in 
molecular terms.
As the molecular basis of depression after stroke is not well 
understood, we aimed to take a discovery approach to identifying 
molecular pathways impacted by depression in stroke survivors. 
We sought to use a proteomics technique that is capable of iden-
tifying and quantifying a large number of biological entities. Our 
research aim was to identify and quantify peptides to be used 
to understand the biological mechanisms associated with PSD 
symptoms. Thus, a data-driven discovery proteomics methodol-
ogy was used to investigate the biological mechanisms associated 
with depression etiology 3 months post-stroke. Given the recent 
finding of Zhan et al. (47), we also sought to investigate whether 
this finding could be replicated using a different proteomics 
and analytic approach to that previously reported, in order to 
strengthen the validity of the proteomic profile of PSD. Our 
analysis was conducted at 3 months post-stroke.
First, a label-free quantitation (LFQ) technique was employed 
to examine the blood samples of stroke patients. The LFQ techni-
cally differs from the iTRAQ approach in that the protein samples 
are not pooled or tagged for analysis, and each sample generates 
its own proteomic profile (52). The relationship between protein 
expression and various clinical measurements can then be 
explored instead of comparisons being planned a  priori, thus 
conforming to a discovery approach better suiting our aim. 
Furthermore, it is debatable that iTRAQ provides better quantita-
tion than LFQ approaches, with LFQ shown to perform similarly 
(53) or more accurately (54) than iTRAQ approaches.
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Second, blood serum was chosen compared to EDTA 
 anticoagulated plasma. To date, there has been little or no 
research published comparing the differences between serum 
and plasma blood samples in stroke proteomics. EDTA has been 
shown to be the least proteolytically active of the plasma samples 
and has previously been shown to reveal low abundance proteins 
in healthy patients (55). However, the proteomic and secretomic 
profile of serum may be more suitable for profiling of coagulation 
and complement systems (56). Furthermore, in a small batch 
optimization analysis of these bloods, we found overall increased 
expression of coagulation and complement in serum compared to 
EDTA, as expected (57).
Third, biological pathways and mechanisms were ascertained 
using the gene set enrichment analysis (GSEA) statistical and 
bioinformatics tool. This tool compares the current protein 
expression data from our study to those from the Molecular 
Signatures Database (MSIGDB) (58). The approach of DAVID 
considers gene annotation clustering after statistical procedures 
have identified significant differences in protein expression (59). 
However, the GSEA approach develops an enriched gene set from 
the original expression data and compares them to sets from 
the databases on MSIGDB (58). Using pathway analysis affords 
greater explanatory power in highlighting relationships between 
gene sets and phenotypes that might go unnoticed in a compari-
son of individual proteins. While this is inherently a technique for 
genes and genomic profiling, the statistical approach of database 
list ranking in GSEA has been demonstrated to be applicable to 
mass spectrometry (MS)-based proteomics (60–62). The data-
bases cannot yet interpret the full complexity of the molecular 
proteome as they do not consider protein/protein interactions 
and post-translational modifications. However, despite these 
limitations, GSEA represents one of the best tools currently 
available for understanding cellular pathways (63). Ultimately, 
we aim to show that the proteomics approach is a reliable and 




A subset of 44 stroke patients (30 females and 14 males) were 
obtained consecutively and prospectively from the START_
PrePARE (STroke imAging pRevention and Treatment_Predic-
tion and Prevention to Achieve optimal Recovery Endpoints) 
cohort, a longitudinal stroke cohort study with advanced 
clinical and neuroimaging data conducted in Australia (64). The 
participants were recruited following a first ischemic stroke and 
were over 18  years of age. A diagnosis of ischemic stroke was 
determined by an experienced neurologist using clinical assess-
ments supplemented with computerized tomography (CT) or 
MRI. Further information on inclusion and exclusion criteria for 
this study can be found in protocol papers for START_PrePARE 
(64) and START_EXTEND (65). Patients included were selected 
consecutively from the prospectively collected START_PrePARE 
cohort as patients were being recruited. Patients were not 
excluded if they had a prior history of depression, as our focus 
was to identify biological factors associated with the presence 
of depression in stroke survivors at a particular point in time, 
irrespective of whether depression was present prior to or post-
stroke (64). Inclusion of patients with prior history of depression 
was also important to improve ecological validity and permit 
generalization of findings to clinical populations, given prior 
history of depression in stroke patients.
Design
The data presented in this manuscript were obtained primarily 
at 3 months post-stroke (±7 days), when clinical data and blood 
were collected. Ethics was approved by the Human Research 
Ethics Committee of Austin Hospital, Heidelberg (HREC code: 
H2010/03588), and relevant university and hospital sites. Further 
details on study design are provided in related protocol papers for 
START_PrePARE (64) and START_EXTEND (65).
clinical assessments
The National Institute of Health Stroke Scale (NIHSS) was 
administered by a trained neurologist or health-care professional. 
This measure is designed to be a test of patient neurological status 
and correlates highly with stroke severity (66). Prior history of 
depression was obtained using the two-item Patient Health 
Questionnaire (PHQ-2) (67) at 3–7 (±1) days post-stroke and 
again at 12 months (±7 days) post-stroke. The PHQ-2 is a brief 
screening tool that employs the first two questions of the nine-
item Patient Health Questionnaire (PHQ-9) (68) and shares high 
correlation, interrater reliability, and internal consistency with 
the PHQ-9 (69).
Depressive symptoms were assessed at 3  months post-
stroke using the Montgomery–Åsberg Depression Rating Scale 
(MADRS). The MADRS is a validated measure in clinical depres-
sion research (70, 71), and was delivered using the structured 
interview guide (SIGMA) (72). This is a standardized interview 
format for the MADRS, providing the clinician with more 
versatility to probe the circumstances surrounding depression 
symptomatology compared to a self-report method. The SIGMA 
format is reported to have higher reliability than the self-report 
MADRS (72). The MADRS_SIGMA was selected as it is a stand-
ardized and validated observer-rating of depression at a point in 
time (72). It was administered by a health-care professional (stroke 
nurse, occupational therapist, or doctor) specifically trained in 
the administration of this assessment. Assessors used SIGMAs, 
detailed protocol manuals, and training videos to enhance stand-
ardization in the administration of the tool. Non-verbal supports 
were available to patients who were aphasic. Higher scores on the 
MADRS indicate more depressive symptoms.
Global cognitive impairment was screened using the Montreal 
Cognitive Assessment (MoCA), a validated screening measure of 
cognitive impairment in dementia and post-stroke recovery (73). 
While positive scores on the MoCA indicate optimal cognitive 
functioning, an adjusted cutoff score of <23 in stroke popula-
tions suggests cognitive impairment (74). The modified Rankin 
Scale (mRS) was used to measure functional disability. It is an 
interview based measure, with lower scores indicating lesser 
levels of observable functional impairment in daily life (75). All 
assessments were administered by a health-care professional, 
specifically trained in the administration of these assessments. 
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Background details on age, gender, subtype of acute ischemic 
stroke, and thrombolysis were also obtained.
Blood collection and serum separation
Blood samples were obtained by venipuncture at the 3-month 
follow-up assessment. All samples were collected in plastic 
serum-separating tube (SST) vacutainers and were allowed to clot 
at ambient temperate for 30 min. The tubes were then centrifuged 
at 1100–1300  g at room temperature, and the resulting serum 
was aliquoted into Eppendorf 4 × 2.0 mL tubes and immediately 
stored at −80°C. Upon moving blood samples from hospital sites 
to the central laboratory, temperature was kept at −20°C prior to 
transfer into a −80°C freezer.
sample Preprocessing and Trypsination
Ten microliters of serum from each patient was first stabilized 
in 100 μL of 8M urea pH = 8.3 and stored at −80°C until used. 
For proteomic analysis, the stabilized samples were processed as 
follows: 20 μL protein solution was added to 90 μL of 8M urea 
pH = 8.3 and reduced for 5 h with 1 μL of 200 mM tris(2-car-
boxyethyl)phosphine (TCEP). After this, samples were alkylated 
for 1 h at 25°C in the dark with 4 μL of 1M iodoacetamide (IAA). 
In sample, digests were performed overnight (37°C) by addition 
of 1 μg of trypsin (Promega, Madison, WI, USA) and 900 μL of 
50 mM Tris pH = 8.3, followed by a second digestion step with 
1 μg trypsin and an additional incubation of 4 h at 37°C. Two 
hundred microliters of the digested solution were collected and 
dried by SpeedVac centrifugation. The digested proteins were 
resuspended in 100 μL of 1% (v/v) formic acid and centrifuged at 
14,000 rpm for 2 min. The solid-phase extraction was performed 
with Empore reversed-phase extraction disks (SDB-XC reversed-
phase material, 3M) according to Ishihama et al. (76) with the 
following modifications: the membrane was conditioned with 
50 μL of 80% (v/v) acetonitrile, 0.1% (w/v) trifluroacetic acid, 
and then washed with 50 μL of 0.1% trifluroacetic acid before 
the tryptic peptides were bound to the membrane. The bound 
peptides were eluted by 50 μL 80% (v/v) acetonitrile, 0.1% (w/v) 
trifluroacetic acid, and dried in a SpeedVac centrifuge.
Mass spectrometry
Tryptic peptides reconstituted in 0.1% formic acid and 2% 
acetonitrile (buffer A) were analyzed by LC-ESI–MS/MS on a 
LTQ-Orbitrap Elite (Thermo-Fisher Scientific). Peptides were 
loaded onto a trap column (C18 PepMap 100 μm i.d. ×  2  cm 
trapping column, Thermo-Fisher Scientific) at 5 μL/min for 6 min 
before switching the precolumn in line with the analytical column 
(Easy-Spray 75 μm i.d. × 50 cm, Thermo-Fisher Scientific). The 
separation of peptides was performed at 250  nL/min using a 
linear acetonitrile gradient of buffer A and buffer B (0.1% formic 
acid and 80% acetonitrile), starting from 5% buffer B to 60% over 
300 min. This final separation step is equivalent to fractionation 
and was conducted in order to avoid potential biases and increased 
sample variability due to depletion. Although it is impossible to 
eliminate dynamic range issues in serum samples, this technique 
greatly increases the dynamic range detectable in our experiment.
Data were collected in data-dependent acquisition mode 
using m/z 300–1500 as MS scan range; CID MS/MS spectra 
were collected for the 20 most intense ions. Dynamic exclusion 
parameters were set as follows: repeat count 1, duration 90 s, and 
the exclusion list size was set at 500 with early expiration disabled. 
Other instrument parameters for the Orbitrap were the following: 
MS scan at 120,000 resolution, maximum injection time 150 ms, 
AGC target 1 × 106, and CID at 35% energy for a maximum injec-
tion time of 150 ms with AGT target of 5000. The Orbitrap Elite 
was operated in dual analyzer mode with the Orbitrap analyzer 
being used for MS and the linear trap being used for MS/MS. 
This procedure was performed on two technical replicates. The 
samples were then analyzed using the in-house Mascot server 
for protein identification. MaxQuant (Max-Planck Institute for 
Biochemistry, Martinsried, Germany) was used to obtain the rela-
tive quantification of identified proteins in the samples. Relative 
intensity or quantification is a measurement of peak height in 
a single sample that is compared to the same measurement in 
other samples. The absolute concentrations of the proteins in the 
sample are not known and require other methodologies to obtain, 
and thus, relative protein expression data cannot be generalized to 
other protein assays. Absolute quantification is possible on a mass 
spectrometer, but requires prior knowledge of target proteins and 
extensive methodologies.
Protein identification and  
label-Free Quantitation
Identification and LFQ of obtained spectra across all 44 sam-
ples was performed using MaxQuant version 1.4.1.2 to obtain 
identified proteins (77). All raw data and complete details of 
MaxQuant parameters and result files have been deposited in 
ProteomeXChange and are available with accession number 
PDX003494. Identification of peptides and proteins was per-
formed internally by MaxQuant using the Andromeda (77) 
search engine to search against all reviewed and unreviewed 
human proteins in the Uniprot database (August 2013; 133,798 
entries in total). Common contaminants and decoys (reversed 
sequences) were included automatically by Andromeda. Prior to 
searching, MS/MS spectra were filtered according to MaxQuant 
default settings for ion trap MS/MS spectra by retaining only 
the top eight peaks per 100  Da. Main search, precursor mass 
tolerance was set to 4.5 ppm, and MS/MS tolerance to 0.5 Da. 
Carbamidomethylation of cysteines was set as a fixed modifica-
tion, and N-term acetylation and oxidation of methionine were 
included as variable modifications. Up to two missed cleavages 
were allowed, and peptides were required to be at least seven 
amino acids in length. False discovery rate (FDR) cutoffs for 
both peptides and proteins in the database search were set to 1%. 
Both unique and razor peptides were used for quantitation with 
a minimum of two peptides including at least one unique peptide 
required to calculate a protein quantitative value. The “match 
between runs” setting in MaxQuant was used to transfer peptide 
identifications from one run to another on the basis of matching 
retention time and mass-to-charge ratio.
Data Preprocessing and analysis
The initial output from MaxQuant consisted of 515 protein 
groups. After removal of contaminants, the list was shortened 
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to 475 protein groups. The LFQ signal intensity was log2 
 normalized to account for naturally skewed intensity values (78) 
and averaged over technical replicates. The discovery approach 
here employs relative quantification instead of absolute, and 
as such, it was better suited to examine a collection of genes/
proteins as ontologies of biological structures or pathway 
processes to extract biological significance from the proteom-
ics data and understand the systems involved in depression 
symptoms post-stroke (63). As relative protein expression is 
limited to comparison within the study or similar MS-based 
studies, pathway analysis provides greater explanatory power 
than traditional statistical biomarker approaches. Thus, the 
resulting protein group expression data were reduced to gene 
names then paired with the continuous MADRS scores to pre-
pare for GSEA (Broad Institute, MIT). GSEA allows for a robust 
comparison of continuous phenotypes to gene expression with 
the selection of the “Pearson” metric. All analyses in GSEA were 
conducted with the GENE_SYMBOL chip and default number 
of permutations (1000) on full gene sets from Hallmark, Gene 
Ontology (GO), the Kyoto Encyclopedia of Genes and Genomes 
(KEGG), Biocarta, and Reactome Positional and Immunologic 
Signatures, acquired from MSIGDB v5.00. The Hallmark 
database is recommended as an entry to GSEA analysis, as it 
collects gene sets that represent well-defined biological states 
and processes with expression scores computed from many 
existing gene sets to reduce noise and redundancy, acting as 
the searchable “meta-analysis” of gene sets. GO is the earliest 
but most up-to-date functional gene annotation database and 
encompasses the largest variety of annotations under three 
headings: biological processes, molecular function, and cellular 
component (79). KEGG (80), Biocarta (81), and Reactome (82) 
gene sets are curated from external databases, with each database 
representing different approaches to compiling, such as genome 
sequencing, microarray profiling, and computational methods, 
to build complex networks. Positional gene sets represent the 
locations of genes on chromosomes and cytogenic bands (83), 
while the Immunologic Signatures database is a collection of 
immune responses curated from separate microarray stud-
ies. Included gene sets were no smaller than 15 and no larger 
than 500. As per recommendation by the GSEA program for 
discovery experiments, a FDR of 25% was deemed acceptable 
for statistical significance of enriched gene sets, where there 
is a 75% chance of rejecting a false positive (58). A nominal 
p (nom-p) value based on the statistical significance of each 
individual database is also included for reference. This statistic 
is not adjusted for multiple testing, whereas the FDR value is.
An enrichment score is a Kolmogorov–Smirnov-like ranking 
statistic that reflects the degree to which a set is overrepresented 
at the top (positive enrichment) or bottom (negative enrichment) 
of the list when compared to another list (58). For example, when 
adjusted for correlation with increasing score on a clinical scale, 
such as the MADRS, positive enrichment suggests biological 
upregulation of a given gene list, while negative enrichment sug-
gests downregulation of a gene list with increasing presentation of 
depression symptoms. The normalized enrichment score (NES) is 
the primary statistic used for evaluating and comparing gene sets 
and is understood as (58):
 
NES actual Enrichment Score
 Enrichment Scores against
=
mean (  all
           permutations of the dataset)
 
This analysis yields the “leading edge subset” that refers to the 
cluster of proteins that contribute most to the enrichment score 
and can be interpreted as the genes that are most likely to affect 
change in complex pathway function.
To minimize the possible confound of prior history of depres-
sion on the analysis, the appropriate T-test or non-parametric 
(Mann–Whitney) comparisons were conducted and compared 
with group comparisons with Monte Carlo simulations of the 
MADRS scores in subgroups with and without prior history of 
depression.
resUlTs
Patient Demographics and clinical 
status
The average age of ischemic stroke patients in the sample was 
63.62 years, range 34–87 (SD = 13.52), within the range of previ-
ous epidemiological findings, although younger than the mean 
age of 74.40 years (84). Thirty were males and 14 females. Based 
on the TOAST classification (85), 11 patients had large artery 
atherosclerosis, 7 had cardioembolism, and 11 had small vessel 
occlusion. The remaining 15 patients were unclassified. Nine 
patients were administered thrombolytic tPA within the 4.5-h 
time window and two were unknown. Patient demographics 
and NIHSS score at time of recruitment (i.e., baseline M = 1.39, 
SD  =  1.26  days post-stroke), and clinical characteristics at 
3–7 days and at 3 months post-stroke are presented in Table 1.
The average MADRS score for the sample was 6.40 (SD = 7.42, 
95% CI =  [4.17, 8.63], range 0–26). Thirteen (29.55%) patients 
had a score of >6 but <18, indicating that this sample mostly had 
mild depressive symptoms. Only 4 (9.09%) patients had scores 
within the severe symptoms range. However, a person scoring 
12 in major depressive disorder or 8 post-stroke on the MADRS 
can be considered for treatment (86). The sample presented with 
mild stroke severity at 3 months, with a median NIHSS score of 
0 and range 0–5. Similarly, scores on the MoCA and mRS suggest 
that this sample had relatively few cognitive problems and had 
recovered in daily activities at 3 months from the stroke. A cor-
relation analysis of the MADRS with these clinical measures and 
patient age revealed no significant results at 3 months post-stroke.
Screening on the PHQ-2 revealed that 11 of the 44 patients 
had a prior history of depression. As it was possible that patients 
with a pre-stroke history of depression may be predisposed to 
more severe PSD symptoms, a Mann–Whitney comparison was 
conducted to test heterogeneity of MADRS scores between those 
with and without prior history of depression. Preliminary analysis 
suggested that the distributions of both groups were similar, and 
thus, the combined median metric is used (87). After running 
a Monte Carlo simulation for 1,000,000 samples at 99% CI to 
account for low sample sizes, it was found that patients with a 
previous history of depression (Mdn = 5.00) did not significantly 
differ from patients without any history (Mdn = 2.50), U = 165.00, 
TaBle 2 | size of gene set databases searched in gsea and 
corresponding number of enriched sets adjusted for FDr.
gene set 
database
gene sets enriched  
gene sets
significantly enriched  
gene sets (FDr <25%)
Hallmark 50 3 2
Gene Ontology 1454 25 0
KEGG 186 2 2
Biocarta 217 1 1
Reactome 674 7 3




These gene sets are publicly available at http://software.broadinstitute.org/gsea/
msigdb/collections.jsp.
TaBle 1 | Patient characteristics at baseline, 3–7 days, and 3 months 
post-stroke.










Separated or divorced 6 (13.6)
Other 2 (4.5)
Working status, n (%)
Employed 25 (56.8) 14 (32)
Given up work – 7 (16)
Returning to work – 4 (9)
Homemaker 1 (2.3) 1 (2)
Retired 18 (40.9) 18 (41)
Living situation, n (%)
Home alone 9 (20) 8 (18.2)
Home with others 34 (77) 34 (77.3)
Retirement home 1 (2) 1 (2.3)
High level care nursing home – 1 (2.3)
Schooling completed (years), 
mean (SD)
11.81 (3.66)
NIHSS (1–42), mean (SD) 3.84 (4.03) 1.68 (0.33) 0.36 (0.12)
mRS (0–6), median (IQR) 0.00 (0.00)b – 1.00 (2.00)
MoCA (0–30), mean (SD) 25.70 (0.43) 26.70 (0.45)
MADRS (0–60), mean (SD) 7.16 (5.75) 6.40 (7.42)
aBaseline measurements were taken at M = 1.39, SD = 1.26 days post-stroke, i.e., at 
time of recruitment to the study.
bThis mRS score was taken at recruitment and assesses pre-stroke functioning.
NIHSS, National Institute of Health Stroke Scale; 1–42; <5 suggests mild stroke 
severity, with 42 being most impaired; mRS, modified Rankin Scale; range: 0–6, with a 
score of 1 indicating no significant disability, despite symptoms, and able to carry out all 
usual duties and activities; MoCA, Montreal Cognitive Assessment; range: 0–30, <23 
mild global cognitive impairment; MADRS, Montgomery–Åsberg Depression Rating 
Scale; 0–60, >6 suggests presence of depressive symptoms, >17 indicates experience 
of a major depressive episode within 2 weeks.
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z = −0.591, Monte Carlo p =  0.565 [99% CI =  (0.563, 0.566)]. 
Following this validation, it was possible to continue with the 
available range of MADRS scores without having to categorize 
based on prior history of depression.
gene set enrichment analysis
Peptides (n =  475) from the proteomic analysis were analyzed 
to reveal underlying molecular pathways and gene ontologies 
associated with depressive symptoms. Five different data sets 
(Hallmark, GO, KEGG, Biocarta, and Reactome) were interro-
gated to identify enriched data sets. Multiple databases were used 
in our discovery approach to not only explore a comprehensive 
range of possible pathways (given the fact that each database is 
constructed differently) but also to identify commonalities across 
databases, thus strengthening the robustness and generalizability 
of our findings.
Of the gene set databases that were entered in GSEA (Table 2), 
Positional and Immunologic Signatures did not return enriched 
sets. With the exception of GO, all databases showed significantly 
enriched gene sets pertaining to complement cascade activation 
or general immune upregulation/downregulation. All sets were 
negatively enriched when compared with increasing MADRS 
score, suggesting significant protein downregulation with 
increasing level of depressive symptoms. There was also no 
clear enrichment pattern that would associate individual genes 
with MADRS scores. However, there are slight variations in set 
size and top gene contributors that reflect the differences in the 
compiling of the databases itself. Thus, although the statistics and 
bioinformatics analysis show that these pathways are associated 
with depression, biological interpretation is dependent upon 
further information from the individual databases. Positional 
gene sets collect data about chromosomal cytogenic band posi-
tioning of the genes involved, while Immunological Signatures 
collect published examples of specific immune activity against 
an immune challenge such as dendritic cell activity in human 
immunodeficiency virus.
hallmark
As the Hallmark gene sets are computed from a collection of 
similar biological processes, this set provides strong support for 
the negative enrichment of this set and associated gene expres-
sions (Table 3). A negatively skewed NES for both coagulation 
and complement Hallmark gene sets correlated against increas-
ing MADRS scores indicates that there is an overexpression of 
downregulated genes in these sets. These genes can be seen in the 
leading edge subset (highlighted in bold), while the other genes 
comprise the structure of the set and are important in affirming 
the construct validity of the obtained sets, which do not signifi-
cantly contribute to the overall magnitude and direction of the 
enrichment score.
Kyoto encyclopedia of genes
Coagulation and complement cascades and systemic lupus 
erythematous (SLE) were implicated in the KEGG database 
(Table 4). In this database, the SLE set is defined by the antigen-
activated complement pathway, demonstrating the characteristic 
molecular cascades of immune dysfunction. Even though SLE is 
a significant risk factor of ischemic stroke (88), as seen from the 
leading edge (Table 4), it is more likely that this set was merely 
expressing statistical enrichment of a gene set that is largely 
TaBle 4 | significantly enriched gene sets and individual gene contributors from the Kegg database.
name nes individual gene contributors FDr nom p
Complement and 
coagulation cascades
−1.377 c5 c4B c8g c1s Kng1 c8a c3 PrOc MBl2 c8B c9 c1Qc F2 c4BPa c1QB serPinF2 Plg 
c6 F11
0.083 0.070
FGB SERPINA5 KLKB1 CFI C2 SERPIND1 CPB2 F10 SERPINC1 F5 MASP1 SERPING1 F13B F12 
A2M C1R FGA VWF C4BPB C1QA CFH C4A PROS1 SERPINA1 CFB C7
Systemic lupus 
erythematous
−1.731 cP s100a12 c9 c1Qc aPOc1 F2 Fn1 Plg 0.019 0.016
C7 C5 C4B C8G C1S C8A C3 C8B C9 C1QC C1QB C6
The genes in bold represent the leading edge subset of genes that contribute most to the enrichment score of the set.
TaBle 3 | significantly enriched gene sets and individual gene contributors from the hallmark database.
name nes individual gene contributors FDr nom p
Coagulation −1.268 cOMP PrOc MBl2 TF c8B c9 aPOc1 F2 PrOZ Fn1 Plg gsn MsT1 F11 0.218 0.157
GP1BA KLKB1 CFI APOC3 C2 ITIH1SPARC HRG CLU CPB2 F10 SERPINC1 PF4 SERPING1 F13B F12 APOA1 
A2M C1R FGA APOC2 VWF C1QA CFH PROS1 SERPINA1 CFB CPN1 ANG C8G C1S C8A C3
Complement −1.662 cP s100a12 c9 c1Qc aPOc1 F2 Fn1 Plg 0.157 0.013
LTF GP1BA KLKB1 C2 ITIH1 CLU CA2 F10 SERPINC1 F5 SERPING1 C1R C4BPB C1QA CFH SERPINA1 CFB 
APOA4 ANG C1S C3
The genes in bold represent the leading edge subset of genes (see Subjects and Methods for overview) that contribute most to the enrichment score of the set.
NES, normalized enrichment score; FDR, false discovery rate; Nom p, nominal p-value.
TaBle 6 | significantly enriched gene sets and individual gene contributors from the reactome database.
name nes individual gene contributors FDr nom p
Immune system −1.651 c7 c5 c8g c1s carD9 c8a c3 icaM1 MBl2 c8B s100a12 c9 c1Qc c4BPa c1QB c6 lBP 0.075 0.029
CRP CFI C2 MASP1 SAA1 SELL CD14 C4BPB C1QA CFH C4A PROS1 B2M CFB
Innate immune system −1.639 c7 c5 c8g c1s carD9 c8a c3 MBl2 c8B s100a12 c9 c1Qc c4BPa c1QB c6 lBP 0.039 0.018
CRP CFI C2 MASP1 SAA1 CD14 C4BPB C1QA CFH C4A PROS1 CFB
Complement −1.334 c7 c5 c8g c1s c8a c3 MBl2 c8B c9 c1Qc c4BPa c1QB c6 0.194 0.126
CRP CFI C2 MASP1 C4BPB C1QA CFH C4A PROS1 CFB
The genes in bold represent the leading edge subset of genes that contribute most to the enrichment score of the set.
TaBle 5 | significantly enriched gene sets and individual gene contributors from the Biocarta database.
name nes individual gene contributors FDr nom p
Complement −1.626 cFB c7 c5 c4B c1s c8a c3 MBl2 c9 c1Qc c1QB c6 0.029 0.029
C2 MASP1 C1R C1QA C4A
The genes in bold represent the leading edge subset of genes that contribute most to the enrichment score of the set.
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comprised of complement. Central to all complement pathways, 
complement component 3 (C3) is one of the main activators and 
mediators of this pathway and was found to contribute highly to 
the negative enrichment score.
Biocarta
The set size of Biocarta complement was only 17, with the major-
ity of genes contributing to the various complement pathways 
and formation of the membrane attack complex (MAC) that is 
involved in attacking target cells. This gene list suggests that both 
mannan-binding lectin 2 (MBL2) and complement component 
1 (C1Q), precursors of both the lectin and classical pathways, 
are downregulated in association with depressive symptoms 
(Table 5). C3 is central to the entire cascade as its activation is 
required for both lectin and classical pathways and attraction of 
the adaptive immune system.
reactome
The Reactome database implicated three gene sets with significant 
negative enrichment in association with MADRS scores, all with 
similar individual gene contributions (Table  6). This database 
consists of a large pathway map of which complement cascades 
are categorized under the innate immune system. The results for 
the complement pathways were similar to those obtained previ-
ously; both classical and lectin pathways are downregulated, and 
MAC activation genes, such as C9 and C6, are underrepresented. 
FigUre 1 | The reactome pathway diagram, demonstrating the primary signaling and functional molecular pathways of the complement system on 
a target cell. In this diagram, multiple activation pathways are shown, eventually effecting cell lysis and breakdown of the target cell. This also shows secondary 
signaling pathways for C3a signaling for pro-inflammation and cytokine activity with C5a-promoting chemotaxic recruitment of inflammatory cells. Retrieved from: 
http://www.reactome.org/figures/Pathway_Illustrations/Complement_Cascade_72_oicr.png; reused under the Creative Commons license.
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These genes are essential to the overall function of the comple-
ment system (Figure 1).
DiscUssiOn
Depression after stroke is a common occurrence, negatively 
impacting functional outcome, response to rehabilitation, and 
quality of life. Utilizing a discovery proteomics approach, this 
study was aimed to find biological associates of depressive 
symptoms (MADRS scores) post-stroke in human serum. This 
was achieved by employing a label-free proteomics workflow, 
utilizing an LTQ Orbitrap with high dynamic range to maximize 
the range of protein identification. Statistical and bioinformatics 
analysis was completed on the GSEA platform on a wide range 
of curated gene set databases. This approach revealed consensus 
among well-developed databases for decreased gene expression 
that was associated with the complement pathways and partial 
support for precursors of the coagulation pathway.
The most important findings of this study are downregulation 
of coagulation and complement cascades in serum bloods from 
stroke patients with increasing level of MADRS-defined depres-
sive symptoms, as depicted by Hallmark, KEGG, Reactome, and 
Biocarta databases. Most PSD studies examine a severe depression 
phenotype. However, we have shown here that even patients who 
have mild depressive symptoms and have recovered well can 
still exhibit biological changes that can be characterized by a 
proteomics approach. Furthermore, even though the analytical 
approach was different, our findings provide additional support 
for those obtained by Zhan et al. (47). Our findings also support 
the dysregulation of the coagulation and complement cascade 
pathway that was identified in Zhan et  al. (47), in serum as 
opposed to EDTA blood samples. The contributing differences in 
individual gene expression are likely due to a number of factors, 
such as stroke timeline, study design, and statistical approaches, 
but most importantly, the use of serum contrasted with EDTA for 
blood preparation. Considering these methodological differences 
between the two studies, finding similar results only provides 
further confirmation for the proteomic profile of stroke and 
strengthens biological understanding of PSD.
From a molecular standpoint, the primary function of the 
complement system can be summarized as formation of the 
MAC on target cells, while secondary functions include sign-
aling for toll-like receptor 4 (TLR4)-mediated inflammatory 
response (89), leading to increased pro-inflammatory cytokine 
levels (90). Complement has been traditionally viewed as a ver-
satile system, conforming to three distinct activation pathways, 
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leading to similar outcomes (91). Of the leading edge subsets of 
the databases searched, it is clear that a majority of the molecu-
lar determinants of the complement system are downregulated 
in relation to mild depressive symptoms. Of note, complement 
component 1q (C1q) and complement component 3 (C3) are 
both integral to the activation of this system, while downstream 
products that contribute to inflammatory signaling and forma-
tion on the MAC (Figure  1) are all downregulated. This may 
indicate perturbation in brain homeostasis following stroke, 
characterized by an ongoing state of lowered resistance to oxida-
tive stress (92) and immune-related changes (93) in maintain-
ing depression symptoms post-stroke. This is further implied 
by the Reactome database analysis, demonstrating negative 
enrichment of calcium-binding protein A12 (S100A12) and 
lipopolysaccharide-binding protein (LBP), attributed to innate 
immune functioning. S100A12 is an established cytoskeletal 
protein involved in the signaling of neutrophil response and a 
candidate biomarker of inflammation (94).
Coagulation is a key process in vascular diseases, especially 
in ischemic stroke where coagulation factors have been iden-
tified as pre-stroke risk factors (95). This process is heavily 
involved in the stroke itself and treatment with tPA (96, 97). 
Coagulation is an ongoing process in serum and deficiencies of 
several proteins, such as protein Z (PROZ) (98), fibronectin 1 
(FN1) (97), and gelsolin (GSN) (99), have been identified to be 
involved in cerebrovascular and cardiovascular diseases. The 
overlap of genes between coagulation and complement sets is 
expected as the coagulation processes have been identified to 
cleave into the central components of the complement system 
(100). The inclusion of both complement and coagulation cas-
cades into one gene set in KEGG compared to the presentation 
of two separate sets in Hallmark illustrates a previous debate as 
to whether the pathways should be considered separately (101, 
102). However, further studies have shown that while comple-
ment deficiencies alone do not increase bleeding frequency 
and coagulation deficiencies alone do not impair immune 
responses, the functions of the two pathways are linked and 
indeed in the case of innate immunity (103, 104). It has been 
suggested that coagulation and complement are involved in a 
feedback loop, where complement activation increases platelet 
activation area on the target cell that in turn augments comple-
ment activity (105). Coagulation has independently been shown 
to be involved in the process of cell death and is associated with 
activation of the kinin–kallikrein pathway and facilitates defen-
sive inflammatory responses by enhancing leukocyte activity 
(106). Finally, binding platelets also have the ability to enhance 
neutrophil activity via TLR4 signaling, a process that is vital to 
phagocytosis (105).
Although a robust association between relative presence of 
depressive symptoms and downregulation of complement and 
coagulation pathway was found in our necessarily small sample 
of mild stroke survivors living in the community, our findings 
need to be interpreted with care, especially as some patients had a 
prior history of depression. We did use a group comparison utiliz-
ing Monte Carlo simulations that indicated that prior depression 
did not significantly impact our findings. Due to the discovery 
approach and the patient’s characteristics of this sample, the 
generalizability of the findings is limited to survivors with mild 
stroke severity.
complement Post-stroke: From acute cell 
Death to immunodepression and 
Depression
Cell death in the brain is the inevitable consequence of any stroke 
damage. In stroke, the first wave of cell death occurs as a result 
of hypoxia. This releases damage-associated molecular patterns 
(DAMPs) that can begin and perpetuate apoptotic and necrotic 
cell death cascades in neighboring neurons. Such molecules can 
include, but are not limited to, intracellular adenosine triphos-
phate and uridine triphosphate that has been leaked into the 
extracellular space, nitric oxide, heat shock proteins, S100 pro-
teins, extracellular calcium ion levels, and cytokines (107, 108). 
The presence of DAMPs on the central side of the blood–brain 
barrier (BBB) are also associated with endothelial damage, which 
further contributes to increased permeability and infiltration of 
immune cells from the periphery (109).
Transcriptomic research has not yet identified pathways 
involved in the timeline of PSD pathogenesis in bloods; however, 
an overview of studies examining the whole blood ribonucleic 
acid (RNA) profiles of different stroke subtypes, including TIA 
in <1  week, has yielded interesting results (110). Functional 
analysis of the genes in these studies has shown that immune 
and homeostasis pathway expression can differentiate between 
cardioembolic and atherosclerosis stroke (111), and Gene 
Ontology clustering in cardioembolic ischemic stroke suggests 
gene expression indicative of cell death, lipid metabolism, and 
metal ion transport. Thus, here we propose that the proteomi-
cally detectable state of the peripheral immune system may be 
indicative of unresolved ischemic damage in the central paren-
chyma, resulting in disruptions to inflammatory, metabolic, and 
homeostatic balance that is related to the transcriptomic profile in 
the early stages of stroke damage (110). While there is no neuro-
biological evidence presented in our study, current knowledge of 
the etiology of PSD suggests that persistent neuroinflammation, 
driven by an increase in pro-inflammatory but also a decrease in 
anti-inflammatory cytokine signaling, is responsible for depres-
sive symptoms post-stroke (22, 112). Indeed, it is possible that 
peripheral immunodepression may be caused by central and 
upstream molecular cascades that include cross BBB cytokine 
signaling (113) or bioavailability of immunoglobulin antibodies 
(114) and leukocyte immune cells (115). Thus, PSD can be con-
sidered as a natural sequelae of incomplete recovery from stroke 
that can be further exacerbated by anxiety from psychosocial 
issues (8).
We have shown that two innate immune pathways in peripheral 
bloods, complement and coagulation, trend toward downregula-
tion at the 3-month phase in correlation with mild symptoms 
of depression. The complement system is largely involved in an 
array of normal and immunoregulatory functions, although its 
role in immunodepression post-stroke has not been explored 
(Table 7). As a whole however, immunodepression after stroke 
is a well-documented and a natural consequence of ischemia, 
but is poorly understood in functional terms (116). Initially, 
TaBle 7 | a brief overview of the complement system in both central and peripheral functioning related to stroke risk, the stroke, and post-stroke 
outcomes, as understood from both human and animal studies.
Pre-stroke function and risk factors stroke (0–48 h) stroke outcomes (48 h+)
Central + C3a regulates neurogenesis in vitro by 
determining differentiation and migration 
of neural progenitor cells (124)
+ Complement inhibition by various methods 
such as C5a antagonists (125) and intravenous 
immunoglobulin (126) are neuroprotective
+ Astrocyte-modulated complement responses 
enhance the ability of microglia to remove cell 
death debris (127)
+ Complement system involved in synaptic 
pruning by opsonization involving 
recruitment of microglia (128)
− Enhances neutrophil adhesion and leukocyte 
activity which leads to further tissue  
damage (129)
+ Complement promotes neurogenesis post-
cerebral ischemia (130)
− Propagation of neuroinflammation and apotopic 
cell death (131, 132)
Peripheral + Constitutes part of the immune system, 
involved in clearance of pathogens via 
opsonization and cell lysis. Can initiate a 
local inflammatory response (50)
− Early elevation of plasma levels of complement 
predict negative functional outcome following 
aneurysmal subarachnoid hemorrhage (133)
− Increased serum C4 levels in patients 
with coronary artery disease predicts 
stroke risk (134)
− Early elevation of plasma levels of complement 
predict negative functional outcome following 
aneurysmal subarachnoid hemorrhage (133)
− C5a induces vasodilation independent 
of histamine (135) and increased central 
venous pressure (136)
− Reduced complement protein expression 
in blood associated with mild depressive 
symptoms (current study)
− Serum C3 levels independently 
associated with myocardial infarctions 
and ischemic events, including TIA (137)
The + denoted functions indicate normal or positive functioning, while the − denoted functions indicate counterproductive functioning. Overall, the complement system is involved 
in regulation of immune function either by localized cell lysis cascades or targeting for removal by phagocytosis. The same is true in both central parenchyma and periphery, where 
microglia are the primary phagocytes in the brain, while neutrophils, dendritic cells, and monocytes are the primary phagocytes in the periphery. However, this distinction no longer 
holds in the event of a stroke, where BBB disruption allows some immune cells to infiltrate from the periphery. The complement system exhibits dual roles in the brain, propagating 
cell death by encouraging the DAMP-initiated signaling cascades of apoptosis but also neuroprotection by removing cellular debris and engaging in synaptic pruning, contributing to 
post-stroke recovery.
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it appears that immunodepression is counterproductive after 
stroke as it may increase the chances of commonly reported sec-
ondary infections such as urinary tract infection and pneumonia 
(117, 118). Additionally, immune suppression is thought to be 
an adaptive response to central inflammation as an autoimmune 
response against the brain would be detrimental to recovery 
outcomes and possibly exacerbate damage (116, 119). There are 
many factors that may maintain poor immune responses and 
recovery in animal models such as induced psychosocial stress 
(120), abnormal BBB permeability (121), and possible ongoing 
antigen-related responses that have yet to be fully characterized 
(122, 123).
There has been little research exploring the role of complement 
and indeed immunity post-stroke in relation to depression. The 
results here suggest that there is ongoing immunosuppression in 
the periphery with mild depressive symptoms, even at 3 months 
post-stroke. Previous research into antigen-presenting cells, such 
as macrophages and dendritic cells, has established that their 
expression is elevated centrally, but downregulated peripherally 
post-stroke (138, 139). A trend toward immune recovery would 
stipulate that a balance has been reached in these cell levels for 
both central and periphery. Indeed, it has also been theorized 
that this discrepancy accounts for the recruitment of peripheral 
dendritic cells into the brain to maintain a central inflammatory 
and immune response (140). Thus, given these lines of evidence, 
it is possible that our current findings reflect an ongoing sub-
acute state of pro-inflammation that has not yet transitioned to 
anti-inflammation (109), manifesting behaviorally as depression 
symptoms and molecularly as peripheral immunodepression of 
the complement and coagulation systems.
limitations and Future studies
The patients in this study were not severely depressed and had 
recovered well after their stroke, with some patients recording a 
history of pre-stroke depression. Furthermore, there was no age-
matched control group present in this study. The current study was 
a pilot to investigate the feasibility of the proteomics approach in 
stroke. While we found a significant association even in a sample 
with mild depressive symptoms and mild stroke severity, future 
studies that employ larger sample sizes with depressive symptoms 
and neurological severity that represent the range commonly expe-
rienced are recommended. Future studies may consider basic or 
laboratory assessment of the immunological condition of patients 
post-stroke as well as the relationship between clinical and/or 
psychosocial factors on PSD. We used a discovery approach where 
the findings can stand alone for the stroke cohort, although it is 
recognized that this approach is not as robust as with age-matched 
controls. Therefore, we recommend future comparison with age-
matched non-stroke controls, with and without depression, to 
enable a more comprehensive interpretation of findings. In addi-
tion, future studies may compare the proteomes of other biofluids, 
such as CSF and urine, of the same patients to develop a better 
understanding of the compartmentalization or relationships of 
BBB and kidney physiology post-stroke. Complement and coagu-
lation functioning can also be assayed in blood in the traditional 
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hematological laboratory setting. From a technical perspective, 
further studies could optimize the comparison of ionic chelation 
properties of anticoagulants as this is not well understood in whole 
blood samples. It is also feasible to employ immunodepletion or 
different fractionation techniques on the mass spectrometer in 
the sample preparation stages to resolve dynamic range and peak 
detection issues for low abundance compounds.
cOnclUsiOn
This study examined the serum proteomic profile of stroke 
survivors at 3  months post-stroke using a label-free approach. 
The findings here and in Zhan et al. (47) are complementary and 
provide a basis for further research into blood proteins recently 
identified to be involved in the pathophysiology of PSD and pos-
sibly in other cerebrovascular diseases with comorbid anxiety. 
Analysis by GSEA on various databases has revealed enriched 
gene sets that are identifiable as complement and innate immune 
processes. As all of these gene sets were negatively enriched when 
correlated with increasing depressive symptoms of ischemic stroke 
survivors, this was interpreted as peripheral immunodepression, 
indicative of unresolved ongoing inflammatory processes in the 
brain. This interpretation is supported by the substantial body of 
literature that has linked PSD etiology to overactive immunologic 
processes, leading to increased inflammatory processes in both 
peripheral and central compartments. While these findings add 
to the growing body of evidence for differentially expressed 
proteins in PSD, more research is needed to characterize their 
molecular processes and how their expressions may change as 
result of the stroke and in development of PSD.
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